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Abstract
Background: The ability to measure T-cell responses to antigens is proving critical in the field of vaccine
development and for understanding immunity to pathogens, allergens and self-antigens. Although a variety of
technologies exist for this purpose IFNg-ELISpot assays are widely used because of their sensitivity and simplicity.
However, ELISpot assays cannot be performed on whole blood, and require relatively large volumes of blood to
yield sufficient numbers of peripheral blood mononuclear cells. To address these deficiencies, we describe an assay
that measures antigen-specific T cell responses through changes in monokine gene transcription. The biological
amplification of the IFNg signal generated by this assay provides sensitivity comparable to ELISpot, but with the
advantage that responses can be quantified using small volumes of whole blood.
Methods: Whole blood or peripheral blood mononuclear cells (PBMCs) from healthy controls and
immunosuppressed recipients of solid organ transplants were incubated with peptide pools covering viral and
control antigens or mitogen for 20 hours. Total RNA was extracted and reverse transcribed before amplification in
a TaqMan qPCR reaction using primers and probes specific for MIG (CXCL9), IP-10 (CXCL10) and HPRT. The
induction of MIG and IP-10 in response to stimuli was analysed and the results were compared with those
obtained by ELISpot.
Results: Antigen-specific T cell responses can be measured through the induction of MIG or IP-10 gene expression
in PBMCs or whole blood with results comparable to those achieved in ELISpot assays. The biological amplification
generated by IFNg-R signaling allows responses to be detected in as little as 25 μL of whole blood and enables the
assay to retain sensitivity despite storage of samples for up to 48 hours prior to processing.
Conclusions: A monokine-based reporter assay provides a sensitive measure of antigen-specific T cell activation.
Assays can be performed on small volumes of whole blood and remain accurate despite delays in processing. This
assay may be a useful tool for studying T cell responses, particularly when samples are limited in quantity or when
storage or transportation is required before processing.
Background
Analysis of T-cell responses to antigen has become cen-
tral to our understanding of immunity against pathogens
[1] and for vaccine development [2]. Over the years,
many methods have been developed to assess antigen-
specific T cells, progressing from limiting dilution and
51Cr release assays to techniques that measure cytokine
production and changes in T-cell phenotype upon
activation [3,4].
Activation of T-cells by antigen leads to the produc-
tion of cytokines, which in turn mediate downstream
effector responses [5]. Of the cytokines secreted, IFNg is
one of the best studied, having been shown to be a
robust marker of T cell activation with levels correlating
with the efficacy of the immune response [6,7]. As a
result, the detection of intracellular or secreted IFNg has
become an accepted surrogate for functional immune
responses to antigen in many circumstances. Of the
techniques available to measure IFNg, ELISpot analyses
are one of the most widely used due to their low cost,
reliability and high sensitivity for detecting low numbers * Correspondence: richard.cornall@ndm.ox.ac.uk
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require purified PBMCs and relatively large volumes of
blood to perform.
IFNg secreted by antigen-activated T-cells binds to
interferon-gamma receptors present on several cell
types, including those of monocyte/macrophage lineage
[9]. Binding causes a conformational change in the
receptor and activation of JAK/STAT second messenger
pathways [10], which in humans leads to the transcrip-
tion of a cluster of genes present on chromosome 4
(4q21) including monokine induced by interferon
gamma (MIG or CXCL9) and interferon gamma-
induced protein of 10 kDa (IP-10 or CXCL10) [11]
(Figure 1).
MIG and IP-10 are inflammatory chemokines predomi-
nantly released by monocytes following stimulation by
IFNg [12,13], which act as part of a feedback loop bind-
ing to the chemokine receptor CXCR3 expressed by acti-
vated T lymphocytes [14]. As only minimal transcription
of these genes occurs in the basal state [15], the biologi-
cal amplification of the IFNg signal by the second mes-
senger signaling pathways provides an opportunity to
improve detection when compared with direct measure-
ment of IFNg [11], however previous experiments have
primarily focused on intracellular detection of MIG at
the protein level in CD14
+ cells via flow cytometry
[11,16]. A report demonstrating the detection of MIG at
the RNA level in association with T-cell responses to a
malaria vaccine supports the idea that this could be used
as a bioassay of antigen-specific responses [16], but the
potential utility of a monokine-based detection system
has not been evaluated systematically.
Therefore, we wanted to know whether an assay mea-
suring the induction of MIG and IP-10 mRNA could be
a sensitive and convenient alternative to ELISpot assays
or other techniques based on the use of antibody
reagents and/or flow cytometry. To this end, we have
developed a protocol using qPCR for MIG and IP-10 to
quantify antigen-specific T cell responses that can be
performed on whole blood or with PBMCs. We show
this assay remains sensitive when tested with small
volumes of blood, despite delays of up to 48 hours
before sample processing and correlates well with the
results of IFNg-ELISpot assays.
Methods
Subject recruitment and collection of samples
Patients attending the Oxford Kidney and Transplant
Units and healthy controls recruited through advertise-
ment were invited to donate whole blood following writ-
ten informed consent. Ethical approval for the study was
granted by the Berkshire Research Ethics Committee
(REC reference 08/H0607/50). Whole blood was col-
lected directly into anticoagulated sodium heparin tubes
(BD, Oxford, UK).
Isolation of PBMCs
Cell separation tubes (Sigma, Gillingham, UK) were
used to isolate peripheral blood mononuclear cells
(PBMCs) from whole blood by density gradient centrifu-
gation. PBMCs were washed twice with sterile PBS
(Fisher Scientific, Loughborough, UK) then counted
before being re-suspended in RPMI 1640 media, supple-
mented with 10% Fetal Calf Serum, 1% L-Glutamine,
1% Penicillin-streptomycin solution, 1% Sodium Pyru-
vate (all from Sigma), 1% HEPES buffer (GibcoBRL,
Scotland, UK), and 0.05 mM 2-Mercaptoethanol (Invi-
trogen, Paisley, UK).
Figure 1 Antigen activated T cells and the monokine assay.I nc o n t r a s tt oE L I S p o ta s s a y sw h i c hc a p t u r ea n dm e a s u r eI F N g produced by
activated T cells, the monokine assay measures the downstream effects of IFNg on mononuclear cells benefiting from the biological
amplification of the signalling.
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Peptide pools (15 amino acids in length with overlaps of
11 amino acids) comprising the immunodominant EBV
antigens BZLF1 and EBNA1, and the CMV-specific anti-
gens pp65, UL-40, IE1 and IE2 were purchased from
JPT (Berlin, Germany). Control peptide pools derived
from human alpha-actin-1 (ACTs) protein (negative
control) and CEF (CMV, EBV and Influenza) peptides
(positive control) were also obtained from JPT (Berlin,
German). All peptides were stored at -20°C as lyophi-
lised powders until used. Peptide pools were dissolved
in DMSO (Sigma) and diluted with Dulbecco’sP B S
(GibcoBRL) according to the manufacturer’si n s t r u c -
tions. The lymphocyte mitogens, Concanavalin A
(ConA) and Phytohemagglutinin (PHA) and the calci-
neurin inhibitor tacrolimus (FK506) were purchased
from Sigma (Gillingham, UK). Recombinant human
IFNg was obtained from Peprotech (London, UK).
IFNg-ELISpot assay
96-well PVDF plates (Millipore, Watford, UK) were
coated with 100 μlo fI F N g monoclonal antibody at 15
μg/ml (clone 1-D1K), (MAbTech, Stockholm, Sweden)
and incubated at 4°C overnight. The next day, plates
were washed 5 times with PBS (Fisher Scientific) then
incubated for 2 hours at 37°C with 200 μl/well of com-
plete media. Peptide pools were added in triplicate to
each plate at a final concentration of 1 μg/ml. PHA and
ConA were used at final concentrations of 5 μg/ml, also
in triplicate. 2 × 10
5 PBMCs were added to each well
and incubated for 18-20 hours at 37°C in 5% CO2.A t
the end of the incubation period, plates were washed 5
times with PBS/0.05% Tween 20 (Sigma) then left at
room temperature for 2 hours after the addition of 100
μlo f1μg/ml biotinylated IFNg antibody (clone 7-B6-1)
(MAbTech). After washing 5 times 100 μl( 1μg/ml)
Streptavidin-ALP (MAbTech) was added for 1 hour at
room temperature, then plates were developed with 100
μl/well of 0.22 μm filtered BCIP/NBT (Pierce, Cramling-
ton, UK). Development continued until spots appeared
in the positive control wells. Spots were counted using
an automated plate reader, AID ELISpot (AID, Strass-
berg, Germany), with AID ELISpot software Version 3.5,
(CADAMA Medical Ltd, Stourbridge, UK).
Monokine Assay
PBMCs or whole blood were aliquoted into 96-well
round-bottom plates (Greiner, Gloucestershire, UK)
before the addition of peptide pools, mitogen or recom-
binant IFNg (all in triplicate). Plates were incubated for
18-20 hours at 37°C, in 5% CO2 before RNA extraction
using an RNeasy Mini Kit (PBMCs) or QIAamp RNA
Blood Mini Kit (whole blood) according to the manu-
facturer’s instructions. Extracted RNA was reverse
transcribed using Superscript First-Strand Synthesis Sys-
tem for RT-PCR (Invitrogen, Paisley, UK). cDNA quan-
tification was performed in a 10 μl reaction mix using
Taqman Fast Universal Mastermix and the Taqman
Gene Expression Assay (Applied Biosystems, Warring-
ton, UK). The Taqman Gene Expression assays included
primer and probe combinations for MIG (CXCL9)
(Assay ID Hs00171065_m1), IP-10 (CXCL10) (Assay ID
Hs00171042_m1) and the housekeeping gene hypox-
anthine phosphoribosyltransferase 1 (HPRT) (Assay ID
Hs99999909_m1). qPCR was performed on a StepOne-
Plus Real-Time PCR System (Applied Biosystems).
Experimental triplicates were carried through each step
of the protocol. qPCR data are expressed as fold induc-
tion (RQ value) of MIG or IP-10 normalized to expres-
sion of the housekeeping gene HPRT. RQ is a function
of the Ct value, where Ct is the number of PCR cycles
required to produce a sustainable amplification in the
fluorescent signal above the background threshold. ΔCt
i st h ed i f f e r e n c eb e t w e e nt h eC t value for the house-
keeping gene and the Ct value for the gene of interest e.
g. MIG. ΔΔCt is the ΔCt value of the stimulated sample
subtracted from the ΔCt value of the reference (negative
control). RQ is calculated as 2
-ΔΔCT.
The efficiency (or E value) of the quantitative PCR
reactions was calculated from a standard curve of MIG
and IP-10 induction following stimulation with increas-
ing concentrations of recombinant IFNg. The average E
values for whole blood and PBMCs were 0.997 and
0.998 respectively (with no difference between MIG and
IP-10). The human acute monocytic leukaemia cell line
THP-1 (ATCC, Middlesex, UK) was used for in vitro
analyses, and as an external control. To facilitate inter
and intra-patient comparison RQ values were routinely
normalized to the mean fold induction of MIG and
IP-10 in response to the negative control.
Data analysis
Statistical analyses were performed with GraphPad
PRISM Version 5 (GraphPad Software Inc, California,
USA). Differences between groups were analysed by
one-way analysis of variance (ANOVA) or independent
t-tests. Normality was assessed using the D’Agostino-
Pearson omnibus test. Statistical significance was
defined as p < 0.05. Data from monokine assay are pre-
sented as the mean and 95% confidence interval calcu-
lated from mean, maximum and minimum RQ values
from experimental triplicates and ELISpot data as the
mean ± SEM from triplicate wells.
Results
Recombinant IFNg induced MIG and IP-10 in culture
To discover whether the induction of MIG and IP-10
mRNA could be used as a robust measurement of
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initially studied the effects of recombinant IFNg added
directly to freshly isolated PBMCs or control THP-
1cells. 2 × 10
5 cells/well were incubated for 16 hours
with medium alone or 10-10,000 pg/ml IFNg.E x p e r i -
mental triplicates were carried through each step of the
assay and all assays were performed a minimum of five
times. Up-regulation of both MIG and IP-10 was detect-
able at all concentrations of IFNg tested compared with
unstimulated controls, although at the lowest concentra-
tion (10 pg/ml) only IP-10 induction was significantly
increased above baseline (fold induction, RQ = 3.4, p =
0 . 0 1 3f o rI P - 1 0a n dR Q=2 . 6 ,p=0 . 1 6f o rM I G ) ,s u g -
gesting that IP-10 may be more sensitive for the detec-
tion of low concentrations of IFNg (Figure 2A-C). To
further explore the relationship between the induction
of MIG and IP-10, this time in the context of antigen-
activated T cells, we analysed the changes in gene tran-
scription in samples from 23 different individuals stimu-
lated with a variety of peptides (Figure 2D). The
correlation between the induction of MIG and IP-10 in
these samples was highly significant r
2 = 0.9885.
Antigen-specific responses can be measured in whole
blood or PBMC
A significant limitation of ELISpot assays is the require-
ment to isolate PBMCs. Because the monokine assay
measures the downstream effects of IFNg on gene tran-
scription, we questioned whether it would be possible to
perform these assays using whole blood. To test whether
the induction of IP-10 and MIG could provide a sensi-
tive measure of IFNg production by antigen activated T
cells ex vivo, we incubated whole blood (100 μl) or
PBMCs (2 × 10
5) from individuals with known respon-
siveness to the EBV antigen BZLF1 by ELISpot, with
overlapping peptide pools covering BZLF1 or human
actin (ACTs). The addition of 10,000 pg/ml recombi-
nant IFNg is shown for comparison (Figure 3). (100 μl
of whole blood was chosen on the basis that the average
yield of PBMCs from the donors was ~2 × 10
6/ml). This
experiment showed equivalent (p > 0.05) up-regulation
Figure 2 Induction of MIG (Panel A) and IP-10 (Panel B). PBMCs
from healthy donors were stimulated with increasing concentrations
of recombinant human IFNg. The correlation between dose of IFNg
and MIG expression (A) was r
2 = 0.94, and with IP-10 expression (B)
was r
2 = 0.90. Similar results were obtained using the mononuclear
THP-1 cell line (data not shown). Columns show the mean RQ value
and 95% confidence intervals calculated from triplicate wells. (C)
The relationship between the induction of MIG and IP-10 following
the addition of recombinant IFNg (from A&B above), with reference
to the induction of MIG (dashed line). (D) The correlation between
MIG and IP-10 induction in 23 subjects following stimulation with a
variety of peptides (r
2 = 0.9885).
Figure 3 Comparison of MIG and IP-10 induction in whole
blood vs. PBMCs. Whole blood (100 μl) clear bars or PBMCs (2 ×
10
5) filled bars were incubated with peptides spanning the EBV
antigen BZLF1, human actin (ACTs) or recombinant IFNg (10,000pg/
ml) for 18-20 hours before lysis and RNA harvesting. The induction
of MIG (Panel A) and IP-10 (Panel B) gene expression are shown
normalized to the negative control (ACTs). Columns show the mean
RQ value and 95% confidence intervals calculated from triplicate
wells. Results are representative of five individual experiments.
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to the negative control in both PBMCs (p = 0.0003 for
IP-10 and p = 0.0008 for MIG) and whole blood (p <
0.0001 for IP-10 and MIG).
Effects of sample storage on assay reproducibility
A further practical concern in planning and executing suc-
cessful experiments in the clinical setting are delays before
samples are processed, especially when they are collected
in the field. Therefore, we asked next to what extent the
signal from the monokine assay would be able to survive
intact without rapid processing. Blood from healthy con-
trols with known responsiveness to BZLF1 was divided
for processing as either whole blood (100 μL) or PBMCs
(2 × 10
5). Whole blood samples were incubated with anti-
gen immediately or after 24 or 48 hours storage at room
temperature or 4°C. PBMCs were assessed fresh or after 2
weeks or 2 months storage in liquid nitrogen (Figure 4).
These experiments showed that antigen-specific responses
in whole blood did not significantly degrade despite up to
48 hours at either room temperature or 4°C (Figure 4A
and 4B). Although careful cryopreservation of whole blood
samples has previously been reported to maintain lympho-
cyte viability and functionality [17], this resulted in almost
complete loss of the antigen-specific response, and only
minor preservation of the response to mitogen (data not
shown). Therefore reliable cryopreservation depends on
the isolation of PBMCs, which can be stored for up to 2
months without any loss in sensitivity of the assay (Figure
4C and 4D).
Sensitivity with reduced numbers of PBMCs or
volume of whole blood
Encouraged by the whole blood response, we questioned
whether the biological amplification of the IFNg signal
in monocytes might permit the detection of meaningful
responses with lower PBMC numbers or smaller
volumes of whole blood. Decreasing the number of
PBMCs resulted in a predictable reduction in the mag-
nitude of the response to BZLF1; however responses
still remained detectable above background when as lit-
tle as 25 μl of whole blood (Figure 5) or 50,000 PBMCs
were used (Additional file 1). Preservation of the
response to exogenous IFNg despite a reduction in
Figure 4 Effects of storage on assay sensitivity. Whole blood
(Panels A & B) or PBMCs (Panels C & D) were stored for variable
periods of time at room temperature (RT), 4°C (whole blood) or -80°
C (PBMCs) before stimulation with BZLF1 or PHA for 18 hours
followed by RNA extraction. Induction of MIG (Panels A&C) and IP-
10 (Panels B&D) mRNA transcripts are shown normalized to the
negative control (ACTs). Columns show the mean RQ value and
95% confidence intervals calculated from triplicate wells. Results are
representative of three individual experiments.
Figure 5 Reducing the volume of whole blood. The sensitivity of
the assay to detect antigen-specific T cell responses despite a
reduction in sample volume was assessed using healthy controls
with known responsiveness to the immunodominant EBV antigens
BZLF1 and EBNA1. A statistically significant increase in both MIG
and IP-10 (data for IP-10 is shown) could be detected following
stimulations performed in as little as 25 μL of whole blood.
Columns show the mean RQ value and 95% confidence intervals
calculated from triplicate wells (** = p < 0.01, *** = p < 0.001).
Figure 6 Correlation between monokine and ELISpot assays.A )
Responses to the CEF pool, EBV and CMV peptides and PHA were
analysed in PBMCs from 25 subjects. The correlation between the
induction of MIG gene transcription in the monokine assay (y axis)
and number of spot forming units (SFU)/million PBMCs (X axis) was
(r
2 = 0.592, p < 0.0001). B) Similar analysis as A) comparing MIG
induction in whole blood samples with ELISpot from 10 further
donations (r
2 = 0.67292, p = 0.0037).
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numbers, rather than mononuclear cell numbers limit
the response (Additional file 1).
Comparison of monokine and IFNg-ELISpot assays
As ELISpot assays are the method of choice for measur-
ing antigen-specific T cells in many laboratories, we
next assessed whether responses detected using the
monokine assay would be comparable to those achieved
by ELISpot. In initial experiments we compared
responses using PBMCs from2 5s u b j e c t sp l a t e da t2×
10
5/well in triplicate, stimulated with a variety of pep-
tides (CEF pool, BZLF1, EBNA1, UL-40, pp65, IE1 and
IE2) or mitogen (PHA). Fold induction of MIG and IP-
10 were compared to the number of spot forming units
(SPU) seen by ELISpot (Figure 6A). The correlation
between MIG induction and SPU/million PBMCs was
r
2 = 0.592 (p < 0.0001). The correlation between MIG
and IP-10 induction was r
2 = 0.981.
Having confirmed a highly significant relationship
between the results of ELISpot and monokine assay
using PBMCs, we proceeded to assess whether a similar
relationship might be evident with whole blood. T-cell
responses to stimulation with the CEF peptide pool,
CMV or EBV peptides as above, were measured in a
further 10 samples using 100 μl/well of whole blood for
the monokine assay or 2 × 10
5 PBMCs/well for the ELI-
Spot assay (Figure 6B). The correlation between the fold
increase in MIG in the monokine assay and SPU/million
PBMCs in the ELISpot assay was r
2 = 0.6729 (p <
0.0037). Except in one case, where low-level induction
of MIG and IP-10 was seen when the ELISpot was con-
sidered negative (21 fold-induction of MIG vs. 7 SPU/
million PBMCs), there was concordance between ELI-
Spot and monokine assay results.
Effects of immunosuppression
A clinically important situation for the detection of anti-
gen-specific responses is in the immunocompromised
host. Therefore, we wanted to test the monokine assay
in this setting, particularly in light of the potentially
modulating effects of immunosuppressant medications
on JAK/STAT signaling [18]. Accordingly, we analysed
responses to peptides or mitogen in two renal transplant
recipients, one with uncontrolled CMV viremia and one
with resolving CMV viremia (Figures 7A-C and 7D-E
respectively). 2 × 10
5 PBMCs were stimulated (in tripli-
cate), and the number of spot-forming units measured
by ELISpot compared with the fold induction of IP-10
and MIG. The average number of spots seen in the
negative controls wells was subtracted from each well in
the ELISpot assay to account for any background activa-
tion while monokine assay results were normalised to
the ACTs response, so that net antigen-specific
Figure 7 Comparison of monokine and ELISpot assays in an
immunosuppressed patient. Induction of MIG and IP-10 were
compared with the number of spot forming units detected by
ELISpot in two patients with CMV viremia. Patient A (Panels A-C)
had uncontrolled CMV viremia with persistently elevated viral titres.
Patient B (Panels D-F) had resolving viremia (decreasing viral titres).
Responses to peptides from human actin (ACTs), EBV (BZLF1), and
early (IE-1&IE-2) and late (pp65&UL-40) CMV antigens as well as PHA
were measured ELISpot responses are shown as the mean ± SEM
from triplicate wells following subtraction of the average number of
spots seen in the negative control (ACTs) wells (1 for Patient A and
72 for Patient B). Monokine assay results are presented as the mean
RQ value and 95% confidence interval normalized to the negative
control (ACTs), calculated from triplicate wells. The high background
spot numbers seen for patient B are consistent with widespread
immune activation during recovery from viremia.
Figure 8 Comparison of whole blood and PBMC responses in
the presence of immunosuppression. The effect of the
calcinuerin inhibitor tacrolimus on T cell responses to antigen was
assessed in whole blood (left panel) and PBMCs (right panel).
Incubation with 20 ng/ml tacrolimus (clear bars) but not PBS (black
bars) significantly inhibited antigen-specific T cell responses in
whole blood when compared with PBMCs. Mean RQ values and the
95% confidence interval are shown normalized to the ACTs
response for PBS-incubated samples.
Chakera et al. Journal of Translational Medicine 2011, 9:143
http://www.translational-medicine.com/content/9/1/143
Page 6 of 8responses are shown. The results of the ELISpot assay
were mirrored by the changes seen in MIG and IP-10
gene expression (Figure 7).
Purification of PBMCs from whole blood can lead to
their direct activation, as a result of processing [19,20],
or indirect activation through loss of the inhibitory
effects of therapeutic agents that may be present in vivo.
As a result, the assessment of antigen-specific responses
in whole blood may provide a more clinically meaning-
ful measure of immune function. To test this hypothesis,
we next collected whole blood from healthy donors and
incubated samples in the presence or absence of tacroli-
mus (FK506), an immunosuppressive agent commonly
used to prevent rejection in recipients of solid organ
transplants [21]. Samples were then divided for proces-
sing as whole blood or PBMCs, as described above.
While the induction of MIG or IP-10 following direct
stimulation with recombinant IFNg was unaffected by
incubation with tacrolimus in PBMCs or whole blood,
treatment with tacrolimus significantly inhibited T cell
responses to antigen in whole blood (p = 0.0046 for the
CEF pool) (Figure 8).
Discussion
The ability to accurately quantify antigen-specific
responses has become integral to the study of infectious
diseases, vaccine responses, autoimmunity and allergy [4].
While a variety of techniques exist to detect T cells that
recognize specific epitopes and to analyse the effects of
antigen-induced activation on T cell phenotype, many of
these methods require sophisticated equipment and sig-
nificant expertise to perform. An alternative strategy has
been the measurement of cytokines produced by antigen-
activated T cells, in particular IFNg, which has been
demonstrated to correlate with functional immunity in a
range of clinical settings [22,23].
ELISpot assays have become the standard method to
quantify IFNg production in many laboratories because
they are easy to perform, do not require investment in
expensive equipment (e.g. flow cytometers) and are sen-
sitive for the detection of even low numbers of antigen-
specific cells [24]. However, ELISpot assays have several
important limitations: relatively large volumes of blood
are required to obtain sufficient PBMCs for analysis; the
process of extracting and purifying PBMCs may cause
their activation and alter their phenotype [19,20]; assays
cannot be re-run unless stored samples of cells are
available.
Due to the high burden of infectious diseases in the
developing world, much of the research into T-cell
responses to pathogens is focussed on areas where there
are limited resources for the extraction and purification
of PBMCs and where sample volumes may be restricted
by patient age or co-morbidity. In these settings an
assay that requires only small volumes of blood and
which retains sensitivity despite delays in processing
would provide significant benefits. In this study we have
described a method to assess antigen-specific T cell
responses ex vivo by measuring the up-regulation of
MIG and IP10 gene transcription in mononuclear
cells, in response to IFNg released by activated T cells
(Figure 1). We analysed responses to both chemokines
as a means of internally validating our results and as
expected the correlation between MIG and IP10 induc-
tion was high. Interestingly, the induction of IP-10
appears to be a more sensitive marker in the presence
of low numbers of antigen-specific T cells, possibly
reflecting activation of IP-10 gene transcription by cyto-
kines other than IFNg (Figure 2) [25].
In contrast with previous studies that have evaluated
antigen-specific responses through changes in T-cell
cytokines, we have found the monokine assay to have
several advantages. The biological amplification of the
IFNg signal in monocytes means that co-stimulatory
antibodies are not required [26]; responses remain stable
despite delays in processing (Figure 4), or where samples
sizes are small (Figure 5) and sensitivity equivalent to
ELISpot is achievable [27]. Furthermore, by enabling the
measurements to be made on whole blood, preparation
time is reduced and results may be more representative
of the response in vivo [28,29] (Figure 8).
As the assessment of antigen-specific responses in the
monokine assay is indirect, one limitation of the assay is
its inability to distinguish between a small number of
highly activated T cells and a larger number of less acti-
vated T cells producing the same amount of IFNg.
Although this necessarily reduces the strength of the
relationship between monokine and ELISpot assay
results, overall the correlation between these assays is
good and significantly, non-responders are clearly identi-
fied (Figure 6). Additional benefits of the monkine assay
are that by measuring the effects of IFNg on target cells,
rather than the production of IFNg alone, the monokine
assay provides some confirmation of the downstream
functionality of the T-cell response and once RNA has
been extracted and reverse transcribed, samples can be
stored indefinitely.
Conclusions
The biological amplification of the IFNg signal generated
by the endogenous reporter system described provides a
sensitive and accurate way to measure antigen-specific T
cell activation. The opportunity to perform these assays
on whole blood reduces the time and resource require-
ments for sample processing and may yield results that
are more representative of the in vivo situation. In addi-
tion, the retention of sensitivity despite delays in proces-
sing or where samples are limited in quantity will make
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Additional material
Additional file 1: Detection of antigen-specific responses with
reduced numbers of PBMCs. Induction of MIG (A) and IP-10 (B) mRNA
in response to stimulation with BZLF1 peptides or recombinant IFNg in
decreasing numbers of PBMCs is shown. (Results are presented as RQ
values normalized to the negative control ACTs). Significant induction of
MIG and IP-10 can be detected with as few as 1 × 10
5 cells/well for MIG
or 0.5 × 10
5 cells/well for IP-10.
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